Nerve conduction velocity and evoked potential latencies in streptozotocin-diabetic rats: Effects of treatment with an angiotensin converting enzyme inhibitor

Diabetes/Metabolism Research and Reviews

Volumn 19, Issue 6, 2003, Pages 469-477

  Manschot, Sanne M ^a   Gispen, Willem Hendrik ^a   Kappelle, L Jaap ^a   Biessels, Geert Jan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiotensin converting enzyme; Cerebral dysfunction; Diabetic rat; Enalapril; Evoked potentials; Nerve conduction velocity; Streptozotocin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INSULIN; LISINOPRIL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG MECHANISM; EVOKED AUDITORY RESPONSE; EVOKED BRAIN STEM RESPONSE; EVOKED RESPONSE; EVOKED VISUAL RESPONSE; LATENT PERIOD; MALE; NERVE CONDUCTION; NEUROPHYSIOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SCIATIC NERVE; STREPTOZOCIN DIABETES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; ENALAPRIL; EVOKED POTENTIALS; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; NEURAL CONDUCTION; RATS; REACTION TIME; SCIATIC NERVE;

EID: 0346146974     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.401     Document Type: Article

References (49)

1. Bell DS. Stroke in the diabetic patient. Diabetes Care 1994; 17: 213-219.
2. Mankovsky BN, Metzger BE, Molitch ME, Biller J. Cerebrovascular disorders in patients with diabetes mellitus. J Diabetes Complications 1996; 10: 228-242.
3. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999; 16: 93-112.
4. Sinclair AJ, Girling AJ, Bayer AJ. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. Diabetes Res Clin Pract 2000; 50: 203-212.
5. Ott A, Stolk RP, Van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam study [see comments]. Neurology 1999; 53: 1937-1942.
6. Strachan MWJ, Deary IJ, Ewing FME, Frier BM. Is type 2 diabetes associated with an increased risk of cognitive dysfunction? Diabetes Care 1997; 20: 438-445.
7. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000; 23: 542-549.
8. Jakobsen J, Nedergaard M, Aarslew Jensen M, Diemer NH. Regional brain glucose metabolism and blood flow in streptozotocin-induced diabetic rats. Diabetes 1990; 39: 437-440.
9. Manschot SM, Biessels GJ, Cameron NE, et al. Angiotensin converting enzyme inhibition partially prevents deficits in water maze performance, hippocampal synaptic plasticity and cerebral blood flow in streptozotocin-diabetic rats. Brain Res 2003; 966: 274-282.
10. Rodriguez G, Nobili F, Celestino MA, et al. Regional cerebral blood flow and cerebrovascular reactivity in IDDM. Diabetes Care 1993; 16: 462-468.
11. Pelligrino DA, Albrecht RF. Chronic hyperglycemic diabetes in the rat is associated with a selective impairment of cerebral vasodilatory responses. J Cereb Blood Flow Metab 1991; 11: 667-677.
12. Biessels GJ, Cristino NA, Rutten GJ, Hamers FP, Erkelens DW, Gispen WH. Neurophysiological changes in the central and peripheral nervous system of streptozotocin-diabetic rats. Course of development and effects of insulin treatment. Brain 1999; 122: 757-768.
13. Biessels GJ, Kamal A, Ramakers GM, et al. Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 1996; 45: 1259-1266.
14. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792.
15. Chaturvedi N, Sjolie AK, Stephenson JM, et al. The EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. EURODIAB controlled trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 1998; 351: 28-31.
16. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial [see comments]. Lancet 1998; 352: 1978-1981.
17. Heart Outcomes Prevention Evaluation Study Investigators [see comments]. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
18. Cameron NE, Cotter MA, Robertson S. Angiotensin converting enzyme inhibition prevents development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992; 35: 12-18.
19. Blezer EL, Nicolay K, Bar D, et al. Enalapril prevents imminent and reduces manifest cerebral edema in stroke-prone hypertensive rats. Stroke 1998; 29: 1671-1677.
20. De-Koning P, Gispen WH. Org.2766 improves functional and electrophysiological aspects of regenerating sciatic nerve in the rat. Peptides 1987; 8: 415-422.
21. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates, Academic Press: San Diego, 1986.
22. Shaw NA. The auditory evoked potential in the rat - a review. Prog Neurobiol 1988; 31: 19-45.
23. Funai H, Funasaka S. Experimental study on the effect of inferior colliculus lesions upon auditory brain stem response. Audiology 1983; 22: 9-19.
24. Wada SI, Starr A. Generation of auditory brain stem responses (ABRs). III. Effects of lesions of the superior olive, lateral lemniscus and inferior colliculus on the ABR in guinea pig. Electroencephalogr Clin Neurophysiol 1983; 56: 352-366.
25. Barth DS, Goldberg N, Brett B, Di S. The spatiotemporal organization of auditory, visual, and auditory-visual evoked potentials in rat cortex. Brain Res 1995; 678: 177-190.
26. Kappelle AC, Bravenboer B, van Buren T, Traber J, Erkelens DW, Gispen WH. Amelioration by the Ca2+ antagonist, nimodipine of an existing neuropathy in the streptozotocin-induced, diabetic rat. Br J Pharmacol 1993; 108: 780-785.
27. Cameron NE, Cotter MA, Harrison J. Effect of diabetes on motor conduction velocity in different branches of the rat sciatic nerve. Exp Neurol 1986; 92: 757-761.
28. Wright RA, Nukada H. Vascular and metabolic factors in the pathogenesis of experimental diabetic neuropathy in mature rats. Bruin 1994; 117(Pt 6): 1395-1407.
29. Rubini R, Biasiolo F, Fogarolo F, Magnavita V, Martini A, Fiori MG. Brainstem auditory evoked potentials in rats with streptozotocin-induced diabetes. Diabetes Res Clin Pract 1992; 16: 19-25.
30. Sima AA, Zhang WX, Cherian PV, Chakrabarti S. Impaired visual evoked potential and primary axonopathy of the optic nerve in the diabetic BB/W-rat. Diabetologia 1992; 35: 602-607.
31. Burnard SL, McMurchie EJ, Leifert WR, et al. Cilazapril and dietary gamma-linolenic acid prevent the deficit in sciatic nerve conduction velocity in the streptozotocin diabetic rat. J Diabetes Complications 1998; 12: 65-73.
32. Cotter MA, Mirrlees DJ, Cameron NE. Neurovascular interactions between aldose reductase and angiotensin-converting enzyme inhibition in diabetic rats. Eur J Pharmacol 2001; 417: 223-230.
33. Cameron NE, Cotter MA, Robertson S. Rapid reversal of a motor nerve conduction deficit in streptozotocin-diabetic rats by the angiotensin converting enzyme inhibitor lisinopril. Acta Diabetol 1993; 30: 46-48.
34. Kihara M, Mitsui MK, Mitsui Y, et al. Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve 1999; 22: 920-925.
35. Arezzo JC. The use of electrophysiology for the assessment of diabetic neuropathy. Neurosci Res Commun 1997; 21: 13-23.
36. Yagihashi S. Pathology and pathogenetic mechanisms of diabetic neuropathy. Diabetes Metab Rev 1995; 11: 193-225.
37. Morano S, Sensi M, Di Gregorio S, et al. Peripheral, but not central, nervous system abnormalities are reversed by pancreatic islet transplantation in diabetic Lewis rats. Eur J Neurosci 1996; 8: 1117-1123.
38. van der Sloot P, Mizisin A, Zochodne D. Sulindac in established experimental diabetes: a follow-up study. Can J Neurol Sci 1995; 22: 198-201.
39. Biessels GJ, Smale S, Duis SE, Kamal A, Gispen WH. The effect of gamma-linolenic acid-alpha-lipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats. J Neurol Sci 2001; 182: 99-106.
40. Cameron NE, Cotter MA. Effects of a nonpeptide endothelin-1 ETA antagonist on neurovascular function in diabetic rats: interaction with the renin-angiotensin system. J Pharmacol EXP Ther 1996; 278: 1262-1268.
41. Bachetti T, Comini L, Pasini E, Cargnoni A, Curello S, Ferrari R. Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats. J Mol Cell Cardiol 2001; 33: 395-403.
42. Hallab M, Bled F, Suraniti S, Girault A, Fressinaud P, Marre M. Elevated serum angiotensin-I converting enzyme-activity in type 1, insulin-dependent diabetic subjects with a persistent microalbuminuria. Acta Diabetol 1992; 29: 82-85.
43. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK. Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 1994; 37: 449-459.
44. Harrison-Bernard LM, Imig JD, Carmines PK. Renal AT1 receptor protein expression during the early stage of diabetes mellitus. Int J Exp Diabetes Res 2002; 3: 97-108.
45. Wright JW, Harding JW. Regulatory role of brain angiotensins in the control of physiological and behavioral responses. Brain Res Brain Res Rev 1992; 17: 227-262.
46. Printz MP. Regulation of the brain angiotensin system: a thesis of multicellular involvement. Clin Exp Hypertens [A] 1988; 10: 17-35.
47. Harding JW, Sullivan MJ, Hanesworth JM, Cushing LL, Wright JW. Inability of [125I]Sar1, Ile8-angiotensin II to move between the blood and cerebrospinal fluid compartments. J Neurochem 1988; 50: 554-557.
48. Van Houten M, Mangiapane ML, Reid IA, Ganong WF. [Sar,Ala] angiotensin II in cerebrospinal fluid blocks the binding of blood-borne [125I]angiotensin II to the circumventricular organs. Neuroscience 1983; 10: 1421-1426.
49. Jouquey S, Mathieu MN, Hamon G, Chevillard C. Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats. Neuropharmacology 1995; 34: 1689-1692.